Literature DB >> 9973215

Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.

R B Mandell1, L Z Mandell, C J Link.   

Abstract

We demonstrate a novel method of concentrating radiation for tumor imaging or killing. The rat sodium/iodide symporter gene (rNIS) was cloned into a retroviral vector for transfer into cancer cells to mimic the iodide uptake of thyroid follicular cells. In vitro iodide transport shows that the symporter functions similarly in rNIS-transduced tumor cells and rat thyroid follicular cells. rNIS-transduced and control nontransduced (NV) human A375 melanoma xenografts established in vivo in athymic nude mice were imaged using a gamma camera after i.p. injections of 123I. The rNIS-transduced human A375 melanoma tumors are visually distinguishable from and accumulate significantly more radionuclides than NV tumors. In vitro clonogenic assays confirm efficacy and clearly show that rNIS-transduced A375 human melanoma, BNL.1 ME murine transformed liver, CT26 murine colon carcinoma, and IGROV human ovarian carcinoma can be selectively killed by the induced accumulation of 131I. Thus, NIS-based gene therapy may have both diagnostic and therapeutic applications for cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973215

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

2.  Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats.

Authors:  Hyun Suk Yang; Heuiran Lee; Sung Jin Kim; Won Woo Lee; You-Jung Yang; Dae Hyuk Moon; Seong-Wook Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-25       Impact factor: 9.236

3.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

Review 4.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 5.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

6.  Translational research using the sodium/iodide symporter in imaging and therapy.

Authors:  June-Key Chung; Joo Hyun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-10       Impact factor: 9.236

Review 7.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

8.  Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by 186Re-perrhenate in mice.

Authors:  Christoph G U Riese; Stephan Seitz; Meike L Schipper; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-16       Impact factor: 9.236

9.  Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model.

Authors:  S J Ahn; Y H Jeon; Y J Lee; Y L Lee; S-W Lee; B-C Ahn; J-H Ha; J Lee
Journal:  Cancer Gene Ther       Date:  2010-02-26       Impact factor: 5.987

10.  Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.

Authors:  R Huang; Z Zhao; X Ma; S Li; R Gong; A Kuang
Journal:  Cancer Gene Ther       Date:  2010-10-29       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.